Role of Serum Pepsinogen II and
Diffuse type
Helicobacter pylori
Pepsinogen
Stomach neoplasms
Journal
Gut and liver
ISSN: 2005-1212
Titre abrégé: Gut Liver
Pays: Korea (South)
ID NLM: 101316452
Informations de publication
Date de publication:
15 07 2020
15 07 2020
Historique:
received:
18
03
2019
revised:
25
06
2019
accepted:
12
07
2019
pubmed:
20
9
2019
medline:
14
9
2021
entrez:
20
9
2019
Statut:
ppublish
Résumé
The utility of serum pepsinogen (sPG) I and the sPGI/II ratio as biomarkers for screening individuals with gastric cancer (GC) has not been established in Korea. The aim of this study was to define the role of sPG, especially sPGII, in GC screening. This study enrolled 2,940 subjects, including patients with GC (n=1,124) or gastric dysplasia (n=353) and controls (n=1,463). Tests to determine sPG levels and The sPGI/II ratio was associated with the risk of gastric dysplasia and advanced-stage intestinal-type GC (IGC). In contrast, sPGII was associated with the risk of early-stage diffuse-type GC (DGC). Significantly higher risk was indicated by an sPGI/II ratio <3 for gastric dysplasia and advanced-stage IGC and by sPGII levels ≥20 µg/L for early-stage DGC. Positive HP status showed a stronger association with DGC than with IGC. When sPGII level and HP status were combined, the prevalence of DGC was higher in the ≥20 µg/L sPGII and HP-positive group. Age younger than 40 years was strongly related to early-stage DGC, especially in females (odds ratio, 21.00; p=0.006). sPGII ≥20 ng/mL and positive HP status suggest a risk of early-stage DGC, particularly in young adult females in South Korea.
Sections du résumé
Background/Aims
The utility of serum pepsinogen (sPG) I and the sPGI/II ratio as biomarkers for screening individuals with gastric cancer (GC) has not been established in Korea. The aim of this study was to define the role of sPG, especially sPGII, in GC screening.
Methods
This study enrolled 2,940 subjects, including patients with GC (n=1,124) or gastric dysplasia (n=353) and controls (n=1,463). Tests to determine sPG levels and
Results
The sPGI/II ratio was associated with the risk of gastric dysplasia and advanced-stage intestinal-type GC (IGC). In contrast, sPGII was associated with the risk of early-stage diffuse-type GC (DGC). Significantly higher risk was indicated by an sPGI/II ratio <3 for gastric dysplasia and advanced-stage IGC and by sPGII levels ≥20 µg/L for early-stage DGC. Positive HP status showed a stronger association with DGC than with IGC. When sPGII level and HP status were combined, the prevalence of DGC was higher in the ≥20 µg/L sPGII and HP-positive group. Age younger than 40 years was strongly related to early-stage DGC, especially in females (odds ratio, 21.00; p=0.006).
Conclusions
sPGII ≥20 ng/mL and positive HP status suggest a risk of early-stage DGC, particularly in young adult females in South Korea.
Identifiants
pubmed: 31533397
pii: gnl19091
doi: 10.5009/gnl19091
pmc: PMC7366145
doi:
Substances chimiques
Pepsinogen C
61536-72-9
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
439-449Références
N Engl J Med. 2001 Sep 13;345(11):784-9
pubmed: 11556297
Helicobacter. 2008 Apr;13(2):146-56
pubmed: 18321304
J Gastroenterol Hepatol. 2012 Mar;27(3):598-602
pubmed: 21883453
South Med J. 1979 Jun;72(6):654-6
pubmed: 451645
Am J Epidemiol. 2006 Apr 1;163(7):629-37
pubmed: 16443800
J Gastroenterol. 1995 Aug;30(4):452-60
pubmed: 7550854
Dig Dis Sci. 2014 Jun;59(6):1235-43
pubmed: 24599773
Biol Chem. 2006 Apr;387(4):361-4
pubmed: 16606332
Am J Gastroenterol. 2007 Aug;102(8):1808-25
pubmed: 17608775
Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):989-95
pubmed: 16467114
J Clin Pathol. 1992 Apr;45(4):319-23
pubmed: 1577969
Oncol Rep. 2013 Jul;30(1):43-9
pubmed: 23674196
Gut. 1999 May;44(5):693-7
pubmed: 10205207
Helicobacter. 2018 Dec;23(6):e12542
pubmed: 30303591
Inflammopharmacology. 2007 Feb;15(1):31-5
pubmed: 17323193
World J Gastroenterol. 2005 May 7;11(17):2545-8
pubmed: 15849808
Gastric Cancer. 2006;9(4):245-53
pubmed: 17235625
Clin Chim Acta. 2002 Jun;320(1-2):17-27
pubmed: 11983196
Scand J Gastroenterol. 2000 May;35(5):476-81
pubmed: 10868449
Gut. 2005 Jun;54(6):764-8
pubmed: 15888780
Scand J Gastroenterol Suppl. 1991;180:160-4
pubmed: 2042032
Gastroenterology. 2017 May;152(6):1319-1328.e7
pubmed: 28147224
Int J Cancer. 2008 Aug 15;123(4):917-26
pubmed: 18508314
Acta Pathol Microbiol Scand. 1965;64:31-49
pubmed: 14320675
Infect Immun. 2004 Feb;72(2):1043-56
pubmed: 14742552
Gastroenterology. 1982 Jul;83(1 Pt 2):204-9
pubmed: 7084603
Best Pract Res Clin Gastroenterol. 2006;20(4):651-74
pubmed: 16997151
Am J Gastroenterol. 1998 Jul;93(7):1090-6
pubmed: 9672336
Int J Cancer. 2004 Mar;109(1):138-43
pubmed: 14735480
Gastroenterology. 1971 Apr;60(4):586-604
pubmed: 4324336
Aliment Pharmacol Ther. 1996 Dec;10(6):1021-7
pubmed: 8971305
Histopathology. 2006 Jul;49(1):45-51
pubmed: 16842245
Cancer Epidemiol Biomarkers Prev. 2008 Apr;17(4):838-45
pubmed: 18398025
J Med Screen. 2004;11(3):141-7
pubmed: 15333273
Oncology. 2003;65(3):275-82
pubmed: 14657602
Cancer Res. 1992 Dec 15;52(24):6735-40
pubmed: 1458460
Am J Gastroenterol. 1996 May;91(5):954-8
pubmed: 8633587
J Pathol. 1991 Sep;165(1):69-73
pubmed: 1955938
Gastroenterology. 2007 Aug;133(2):659-72
pubmed: 17681184
J Immunol. 2013 Jan 15;190(2):794-804
pubmed: 23248262
Lab Invest. 2003 May;83(5):635-41
pubmed: 12746473
Clin Exp Med. 2017 Aug;17(3):403-410
pubmed: 27154568
Jpn J Cancer Res. 1995 Dec;86(12):1210-5
pubmed: 8636012
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Cancer Sci. 2005 Oct;96(10):713-20
pubmed: 16232204
J Natl Cancer Inst. 2000 Apr 5;92(7):569-73
pubmed: 10749913
Am J Surg Pathol. 1996 Oct;20(10):1161-81
pubmed: 8827022
Aliment Pharmacol Ther. 2004 Aug 1;20(3):261-70
pubmed: 15274662
Cancer. 1994 Jun 1;73(11):2695-702
pubmed: 8194008
Cancer. 1982 Dec 1;50(11 Suppl):2554-65
pubmed: 7139550
Gut. 2003 Apr;52(4):502-6
pubmed: 12631658